Dihexa vs Cerebrolysin
Ultra-potent synthetic nootropic vs multi-peptide neurotrophic complex — comparing a single-molecule research tool with a clinically used brain-derived preparation.
Last updated: 2026-03-08
Quick Comparison Table
| Category | Dihexa | Cerebrolysin |
|---|---|---|
| Structure | Synthetic hexapeptide derivative (AT4 agonist) | Multi-peptide complex from porcine brain tissue |
| Primary Mechanism | HGF/c-Met pathway activation | Neurotrophic factor mimetic (BDNF/NGF-like) |
| Potency | 10 million times more potent than BDNF at synaptogenesis | Moderate — multi-target, lower individual potency |
| Administration | Oral (research); also SC | IV or IM injection only |
| Clinical Evidence | Preclinical only (no human trials) | Extensive — 50+ clinical trials, approved in 40+ countries |
| Regulatory Status | Research compound (not approved anywhere) | Approved for stroke/dementia in 40+ countries (not US/UK) |
| Safety Data | Minimal — rat studies only | Extensive — well-characterised over 30 years |
| Key Concern | Unknown long-term safety; potential cancer risk (HGF/c-Met) | Prion disease theoretical risk (animal-derived) |
Mechanism of Action
Dihexa
Dihexa Mechanism:
Dihexa (N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide) was developed at Washington State University by Dr. Joseph Harding. It is a stable, orally active derivative of Angiotensin IV.
Key actions: 1. **HGF/c-Met pathway** — Potently activates Hepatocyte Growth Factor signalling, promoting synaptogenesis, dendritic spine formation, and neuronal connectivity 2. **Synaptogenesis** — Creates new synaptic connections between neurons at concentrations 10 million times lower than BDNF 3. **Anti-cognitive decline** — Reversed scopolamine-induced cognitive deficits in rats at picomolar concentrations 4. **Blood-brain barrier penetration** — Orally bioavailable and crosses the BBB
Dihexa's extreme potency is both its appeal and its concern. HGF/c-Met signalling is also active in cancer biology, raising theoretical oncogenic risks with chronic use.
Cerebrolysin
Cerebrolysin Mechanism:
Cerebrolysin is a standardised preparation of low-molecular-weight neuropeptides and free amino acids derived from purified porcine brain proteins via enzymatic proteolysis.
Key actions: 1. **Neurotrophic mimetic** — Contains peptide fragments that mimic BDNF, NGF, CNTF, and GDNF effects 2. **Neuroprotection** — Reduces excitotoxicity, inhibits calpain, and stabilises cytoskeleton 3. **Neuroplasticity** — Promotes dendritic branching and synaptic strengthening 4. **Anti-apoptotic** — Inhibits neuronal programmed cell death via Bcl-2 upregulation 5. **Neurogenesis** — Stimulates neural stem cell proliferation in SVZ and hippocampus
The multi-peptide nature means Cerebrolysin acts on multiple neurotrophic pathways simultaneously — a "broad-spectrum" approach rather than a single molecular target.
Clinical Trial Evidence
Dihexa Clinical Studies
Participants: 0
Duration: 2 weeks
Dihexa reversed scopolamine-induced cognitive deficits at 2mg/kg oral. Effect comparable to BDNF at 10 million-fold lower concentration.
Statistically significant
Participants: 0
Duration: 2 weeks
Oral Dihexa restored spatial learning in aged rats to young adult performance levels in Morris water maze.
Statistically significant
Participants: 0
Duration: In vitro
Dihexa promoted new synapse formation in hippocampal neurons at picomolar concentrations — the lowest effective concentration for any known synaptogenic agent.
Statistically significant
Participants: 0
Duration: In vitro
Confirmed Dihexa acts as an allosteric HGF/c-Met potentiator. Requires endogenous HGF presence for activity.
Statistically significant
Participants: 0
Duration: PK study
Dihexa demonstrated oral bioavailability in rats with measurable CNS concentrations. Crosses BBB effectively.
Statistically significant
Cerebrolysin Clinical Studies
Participants: 1070
Duration: 90 days
Cerebrolysin improved NIHSS and Barthel Index in acute ischaemic stroke patients. Significant functional improvement vs placebo.
Statistically significant
Participants: 280
Duration: 24 weeks
Cerebrolysin 30ml/day IV improved ADAS-cog scores by 3.2 points vs placebo in moderate AD. Clinically meaningful benefit.
Statistically significant
Participants: 142
Duration: 28 days
Early Cerebrolysin administration after moderate-severe TBI improved GCS scores and 6-month functional outcomes.
Statistically significant
Participants: 242
Duration: 24 weeks
Cerebrolysin improved cognitive function (ADAS-cog+) and clinical global impression in vascular dementia patients.
Statistically significant
Participants: 80
Duration: 3 months
Cerebrolysin improved cognitive recovery in children with severe TBI when added to standard care.
Statistically significant
Benefits Comparison
Dihexa Unique Benefits
- Unprecedented potency for synaptogenesis
- Oral bioavailability
- Crosses blood-brain barrier
- Potential for cognitive restoration in neurodegeneration
- Novel HGF/c-Met mechanism
Shared Benefits
- Neuroplasticity enhancement
- Potential cognitive improvement
- Synaptogenesis promotion
- Neuroprotective properties
Cerebrolysin Unique Benefits
- 50+ clinical trials with thousands of patients
- Multi-target neurotrophic action
- Approved in 40+ countries
- Proven in stroke, TBI, and dementia
- 30-year clinical safety track record
Research & Evidence
Dihexa Research
Dihexa research is limited to the Harding laboratory at Washington State University. All data is from rat models and in vitro assays. No human pharmacokinetic, safety, or efficacy data exists. The compound is available from research peptide suppliers but has no clinical development programme.
Cerebrolysin Research
Cerebrolysin has one of the largest clinical evidence bases of any neuropeptide preparation — 50+ clinical trials involving thousands of patients across stroke, TBI, Alzheimer's, and vascular dementia. It is approved in 40+ countries (primarily Asia, Europe, Latin America) but not in the US or UK due to different regulatory standards for biological preparations.
Head-to-Head Analysis
Direct Comparison:
No comparison exists.
Potency vs Breadth: Dihexa is extraordinarily potent at a single target (HGF/c-Met synaptogenesis). Cerebrolysin is moderate-potency across multiple neurotrophic pathways. The "magic bullet vs shotgun" analogy applies.
Evidence Quality: Cerebrolysin has 50+ clinical trials (stroke, TBI, Alzheimer's, vascular dementia) involving thousands of patients. Dihexa has only rat cognitive studies. This is a vast evidence gap.
Safety: Cerebrolysin's 30-year clinical track record provides confidence. Dihexa's unknown safety profile — particularly the oncogenic potential of HGF/c-Met activation — is a significant concern for human use.
Protocol Comparison
Dihexa Protocol
Dihexa Theoretical Protocols (Research-Based):
Dosing: Rat studies: 2mg/kg oral daily. Human equivalent dose extrapolation is uncertain. Research community doses cited: 10-40mg oral or SC daily.
Routes: Oral (primary), sublingual, SC injection.
Duration: Rat studies: 2 weeks. Long-term safety unknown.
⚠️ Warning: No human safety data. HGF/c-Met activation has theoretical oncogenic risk. Extreme caution advised.
Cerebrolysin Protocol
Cerebrolysin Clinical Protocols:
Stroke: 30ml IV daily for 10-21 days, starting within 72 hours of onset.
Alzheimer's Disease: 10-30ml IV daily for 20 days. Repeat cycles every 3-6 months.
TBI: 30-50ml IV daily for 5-10 days post-injury.
Routes: IV infusion (primary) or IM injection (lower doses).
⚠️ Note: Prescription medication. Available in 40+ countries. Not approved in US/UK.
Safety Profiles
Dihexa Safety
Dihexa Safety:
No human safety data. Rat studies show no acute toxicity at therapeutic doses.
Major concern: HGF/c-Met pathway activation is implicated in tumour growth, metastasis, and angiogenesis in multiple cancers. Chronic Dihexa use could theoretically promote tumourigenesis.
This is a genuine, biologically grounded concern — not merely theoretical. Any human use must be considered highly experimental.
Cerebrolysin Safety
Cerebrolysin Safety:
Well-characterised over 30 years. Common side effects: injection site reactions, headache, dizziness (mild, transient).
Rare: Allergic reactions (animal-derived product).
Theoretical: Prion disease risk (porcine-derived brain tissue). Manufacturing process includes steps to inactivate transmissible agents, and no prion cases have been reported.
Contraindicated in: Epilepsy (lowers seizure threshold), severe renal impairment.
The Verdict
These represent opposite ends of the neuroenhancement spectrum. Dihexa offers extraordinary potency through a single pathway but with virtually no safety data and a genuine cancer concern. Cerebrolysin offers validated, multi-pathway neurotrophic support with 30 years of clinical experience but requires IV administration and is not available in the US/UK. For clinical application, Cerebrolysin is the evidence-based choice. Dihexa remains a research tool — fascinating scientifically but far from ready for human use.
Frequently Asked Questions
Conclusion
Dihexa and Cerebrolysin illustrate the tension between pharmacological potency and clinical validation in neuroscience. Dihexa's picomolar synaptogenic activity is scientifically remarkable but carries significant safety unknowns, particularly regarding oncogenic potential. Cerebrolysin's broad neurotrophic profile, while less dramatic, is supported by decades of clinical evidence across multiple neurological conditions. For researchers, Dihexa is a powerful tool for studying HGF/c-Met neurobiology. For clinical applications, Cerebrolysin remains the validated option with the most extensive human data.
Medical Disclaimer
The information provided in this comparison is for educational and research purposes only. Neither Dihexa nor Cerebrolysin is approved for human therapeutic use by the MHRA, EMA, or FDA. This content does not constitute medical advice. Always consult a qualified healthcare professional before considering any peptide or supplement.